Registration Form • Oct 24, 2022
Preview not available for this file type.
Download Source FileS-8 1 ea167481-s8_chinapharma.htm REGISTRATION STATEMENT
As filed with the Securities and Exchange Commission on October 24, 2022
Registration No. 333-
Field: Rule-Page
Field: /Rule-Page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Field: Rule-Page
Field: /Rule-Page
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Field: Rule-Page
Field: /Rule-Page
CHINA PHARMA HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Field: Rule-Page
Field: /Rule-Page
| Nevada | 73-1564807 |
|---|---|
| (State or other | |
| jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| Second Floor, No.
17, Jinpan Road Haikou, Hainan Province, China 570216 +86-898-6681-1730 |
| --- |
| (Address, including zip code, and
telephone number, including area code, of Registrant’s principal executive offices) |
Field: Rule-Page
Field: /Rule-Page
China Pharma Holding Inc.
2010 Long Term Incentive Plan, as Amended
(Full title of the plans)
Field: Rule-Page
Field: /Rule-Page
Unisearch, Inc.
10 Bodie Drive
Carson City, Nevada, 89706
(800) 260-1131
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large
accelerated filer | ☐ | Accelerated
filer | ☐ |
| --- | --- | --- | --- |
| Non-accelerated
filer | ☒ | Smaller
reporting company | ☒ |
| | | Emerging
growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
EXPLANATORY NOTE
This Registration Statement is filed pursuant to General Instruction E to Form S-8 by China Pharma Holdings, Inc., a Nevada corporation (the “Company”), to register 5,000,000 shares of common stock of the Company in addition to those previously registered on the Company’s Registration Statement on Form S-8 (File No. 333-251545) filed with the Securities and Exchange Commission on December 21, 2020, for issuance pursuant to the Company’s 2010 Equity Incentive Plan, as amended. Pursuant to General Instruction E to Form S-8, the contents of such previously filed Registration Statement are incorporated herein by reference, except that the provisions contained in Part II of such earlier Registration Statement are modified as set forth in this Registration Statement.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information.*
Item 2. Registrant Information and Employee Plan Annual Information.*
Field: Page; Sequence: 2; Options: NewSection; Value: 1
Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence
Field: /Page
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed with the Commission are hereby incorporated by reference in this Registration Statement:
| (a) | The
Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Commission on March 30,
2022, containing the Registrant’s audited consolidated financial statements for the years ended December 31, 2021 and
December 31, 2020. |
| --- | --- |
| (b) | The
Registrant’s Quarterly Reports on Form 10-Q filed with the Commission on May 12, 2022 and August 11, 2022 , respectively. |
| (c) | All
other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the
“ Exchange Act ”), since the end of the fiscal year covered by the Annual Report on Form 10-K referred to in (a)
above (other than portions of those documents furnished or not otherwise deemed to be filed). |
| (d) | The
description of our common stock contained in our Registration Statement on Form 8-A filed with the Commission on September 28, 2009,
including any amendment or report filed for the purpose of updating such information. |
| (e) | The
definitive proxy statement on Schedule 14A filed with the Commission on November 15, 2021. |
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act and, to the extent specifically designated therein, Current Report on Form 8-K filed by the Registrant to the Commission that are identified in such forms as being incorporated into this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be part hereof from the date of filing such documents.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
The only statute, charter provision, bylaw, contract, or other arrangement under which any controlling person, director or officer of the Company is insured or indemnified in any manner against any liability which he or she may incur in his or her capacity as such, is as follows:
(a) Subsection 1 of Section 78.7502 of the Nevada Corporation Law empowers a corporation to “indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, does not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and that, with respect to any criminal action or proceeding, he had reasonable cause to believe that his conduct was unlawful.”
Field: Page; Sequence: 3; Options: NewSection; Value: 1
II- Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence
Field: /Page
Subsection 2 of Section 78.7502 empowers a corporation to “indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.”
Subsection 3 of Section 78.7502 further provides that “to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections 1 and 2, or in defense of any claim, issue or matter herein, he must be indemnified by the corporation against expenses, including attorneys’ fees, actually and reasonably incurred by him in connection with the defense.”
(b) The Articles of Incorporation of the Company generally allows indemnification of officers and directors to the fullest extent allowed by law.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
Item 7. Exemption from Registration Claimed.
Not applicable.
Field: Page; Sequence: 4; Value: 1
II- Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence
Field: /Page
Item 8. Exhibits.
The following exhibits are filed as part of this Registration Statement:
| Exhibit Number | Description of Document |
|---|---|
| 5.1* | Opinion of Flangas Law Group (regarding validity of common stock being registered). |
| 10.1 | China Pharma Holdings, Inc. 2010 Long Term Plan dated as of November 12, 2010 (Incorporated by reference from Exhibit A to the definitive proxy statement on Schedule 14A filed with the Commission on November 12, 2010) |
| 10.2 | China Pharma Holdings, Inc. 2010 Long Term Incentive Plan dated as of October 17, 2019 (Incorporated by reference from Appendix A to the definitive proxy statement on Schedule 14A filed with the Commission on November 6, 2019). |
| 10.3 | Amendment No. 2 to China Pharma Holdings, Inc. 2010 Long Term Incentive Plan (Incorporated by reference from Appendix A to the definitive proxy statement on Schedule 14A filed with the Commission on November 15, 2021). |
| 23.1* | Consent of Flangas (included in its opinion filed as Exhibit 5.1) |
| 23.2* | Consent of B F Borgers CPA PC. |
| 24.1 | Power |
| of Attorney (contained in the signature pages hereto) | |
| 107* | Filing Fee Table |
Field: Rule-Page
Field: /Rule-Page
Item 9. Undertakings.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made of securities registered hereby, a post-effective amendment to this Registration Statement which shall include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned Registrant hereby further undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
Field: Page; Sequence: 5; Value: 1
II- Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Haikou, China on October 24, 2022.
| /s/
Zhilin Li | |
| --- | --- |
| Name: | Zhilin Li |
| Title: | President and Chief Executive Officer |
Each of the undersigned members of the board of directors of the Registrant, hereby severally constitutes and appoints Zhilin Li as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and any subsequent registration statements pursuant to Rule 462 of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Zhilin Li | Chairman | |
| of the Board of Directors | October | |
| 24, 2022 | ||
| Zhilin | ||
| Li | Chief | |
| Executive Officer and interim Chief Financial Officer | ||
| (Principal | ||
| Executive Officer and Principal | ||
| Financial | ||
| Officer and Accounting Officer) | ||
| /s/ Heung | ||
| Mei Tsui | Director | October |
| 24, 2022 | ||
| Heung | ||
| Mei Tsui | ||
| /s/ Yingwen | ||
| Zhang | Director | October |
| 24, 2022 | ||
| Yingwen | ||
| Zhang | ||
| /s/ Gene | ||
| Michael Bennett | Director | October |
| 24, 2022 | ||
| Gene | ||
| Michael Bennett | ||
| /s/ Baowen | ||
| Dong | Director | October |
| 24, 2022 | ||
| Baowen | ||
| Dong |
II-4
Field: Rule-Page
Field: /Rule-Page
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.